Source comparison
Ipamorelin Before and After: Research Comparison Table
DEXA body composition trial (n=42) 300mcg twice daily, subcutaneous 16 weeks +4.1kg (+9.0 lbs) −3.2kg (−7.1 lbs) +59% from baseline Bone mineral density increased 1.8% in lumbar spine; no cortisol elevation Recovery marker study (n=38) 200mcg twice daily, subc
This comparison does not assign a generated winner or score.
- DEXA body composition trial (n=42)
- 300mcg twice daily, subcutaneous
- 16 weeks
- +4.1kg (+9.0 lbs)
- −3.2kg (−7.1 lbs)
- +59% from baseline
- Bone mineral density increased 1.8% in lumbar spine; no cortisol elevation
- Recovery marker study (n=38)
- 200mcg twice daily, subcutaneous
- 12 weeks
- +2.6kg (+5.7 lbs)
- −1.8kg (−4.0 lbs)
- +48% from baseline
- Satellite cell activation 34% higher; creatine kinase clearance improved 22%
- Single-dose vs twice-daily comparison (n=30)
- 300mcg once daily vs 150mcg twice daily (same total weekly dose)
- 10 weeks
- Once: +1.2kg; Twice: +3.8kg
- Once: −0.9kg; Twice: −2.7kg
- Once: +22%; Twice: +51%
- Twice-daily dosing produced 3× greater lean mass accretion despite identical weekly totals
- Ipamorelin + resistance training (n=45)
- +3.4kg (+7.5 lbs)
- −2.4kg (−5.3 lbs)
- +52% from baseline
- Type II muscle fiber cross-sectional area increased 18%; recovery scores improved 28%